ReviewCurrent obesity reports2023
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.
Review in Current obesity reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Daily Steps During Nutritional Lifestyle Modification Programs for Obesity Management: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2026Pooled it
- Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D.Journal of endocrinological investigation · 2026Article
- Review
- Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?Diagnostics (Basel, Switzerland) · 2026Article
- Beyond the Scale: Setting Goals for Outcomes Beyond Weight in Evidence-based Obesity Treatment.Current obesity reports · 2026Review
- Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.Frontiers in endocrinology · 2026Article
- The overweight and obesity landscape in italy: data from the Italy cohort of the multi-country IMPACT-O study.Journal of endocrinological investigation · 2025Article
- Metaflammation's Role in Systemic Dysfunction in Obesity: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Jejunoileal side-to-side anastomosis as a promising option for type 2 diabetes.World journal of diabetes · 2025Article
- Time Restricted Eating: A Valuable Alternative to Calorie Restriction for Addressing Obesity?Current obesity reports · 2025Review
- Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.Current obesity reports · 2025Review
- Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps.Clinical endocrinology · 2025Review
- Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?Frontiers in endocrinology · 2025Review
- Combined minimally invasive vagal cranial nerve and trigeminocervical complex peripheral nerve stimulation produces prolonged improvement of severe painful peripheral neuropathy and hyperglycemia in type 2 diabetes.Frontiers in neuroscience · 2025Article
- Weighing your options-intragastric balloon versus semaglutide.Surgical endoscopy · 2024Article
- The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies.Diseases (Basel, Switzerland) · 2024Review
- Pennogenin 3-International journal of molecular sciences · 2024Article
- Article
- Female obesity: clinical and psychological assessment toward the best treatment.Frontiers in endocrinology · 2024Review
- Women with Schizophrenia Have Difficulty Maintaining Healthy Diets for Themselves and Their Children: A Narrative Review.Behavioral sciences (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity. RECENT
findingsObesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established. The evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.